#United States #Pittsburgh #Allegheny Health Network #Hypertension #renal denervation

Introduction

The Allegheny Health Network (AHN) Cardiovascular Institute has recently made remarkable strides in treating patients with treatment-resistant hypertension through a pioneering therapy known as renal denervation. Interventional cardiologists at AHN are experiencing significant health improvements in patients who have struggled with severe hypertension, often unresponsive to conventional treatments.

Understanding Hypertension

High blood pressure, or hypertension, is a pervasive issue affecting nearly 47% of the United States population, according to the American Heart Association. Despite being aware of their condition, about 80% of individuals fail to bring their hypertension under control. Traditionally, treatment options were limited, especially for those with medication-resistant forms of the disease. However, the U.S. Food and Drug Administration granted approval for innovative renal denervation systems in late 2023, providing new hope for patients. The Centers for Medicare & Medicaid Services subsequently announced its commitment to cover these procedures starting in 2025, marking a significant milestone in hypertension management.

The Renal Denervation Procedure

Renal denervation is a minimally invasive surgical technique that targets the overactive nerves in the renal arteries that can cause or exacerbate high blood pressure. The procedure involves inserting a small, flexible catheter into the patient’s groin which then extends to both renal arteries through the femoral vein. By using radiofrequency or ultrasound energy, the cardiologist is able to ablate these problematic nerves, similar to the ablation techniques used for atrial fibrillation treatments. Dr. Ramzi Khalil, an interventional cardiologist at AHN, emphasizes the procedure's significance by stating, "This innovative approach is exciting because it provides the first non-pharmacological therapy for these patients, who previously would have been on multiple blood pressure medications without relief."

Case Studies and Outcomes

The outcomes of early clinical studies, particularly the SPYRAL AFFIRM study using the Simplicity Spyral system by Medtronic, have been promising. AHN's Allegheny General Hospital participated as a leading facility in these trials, showing substantial blood pressure reduction among high-risk cardiac patients without major safety concerns, even six months post-procedure. Moreover, those treated did not require increases in the dosage or number of hypertension medications following renal denervation. Dr. Samer Azouz, another interventional cardiologist at AHN, highlights that this breakthrough could lower the risk of heart attacks and strokes by approximately 20%, with improved blood pressure results being sustained for over a decade.

Patient Experience and Next Steps

A notable advantage of the renal denervation procedure is the recovery process, with many patients able to return home on the same day with minimal discomfort. However, there is a stringent eligibility criterion, requiring patients to have uncontrolled hypertension, specifically blood pressure levels of 140/90 mm Hg or higher, despite active management over six months. Most candidates are typically on at least three medications to manage their condition or are unable to tolerate existing drugs.

Conclusion

The advancements made by the Allegheny Health Network in treating resistant hypertension with renal denervation represent a turning point for thousands of patients struggling to manage their condition. As clinical practices continue to adopt and refine these innovative therapies, there lies hope for better overall health outcomes for hypertensive patients. To check your blood pressure or learn more about this procedure, the public can call 412-DOCTORS for assistance.

About Allegheny Health Network

Allegheny Health Network is a leading integrated healthcare system in western Pennsylvania, comprised of 14 hospitals among other healthcare facilities and services. Employing around 24,000 staff members, AHN is known for offering a wide range of medical services and participating in cutting-edge clinical trials aimed at improving care options for patients across various health concerns, including cardiovascular health.